Gendicine
Sign in to saveGendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists of recombinant adenovirus engineered to code for p53 protein (rAd-p53) and is manufactured by Shenzhen SiBiono GeneTech.
In the Vinony graph
Within Vinony's link graph, Gendicine is referenced by 9 other articles, and connects out to tumor protein p53, United States and European Union.
It sits within the topics Adenoviridae, Chemical articles without CAS registry number and Chemical pages without ChemSpiderID.
Its subject is documented across 5 Wikipedia language editions.
~2 min read
Encyclopedic overview
3 sectionsContents
- Mechanism of action
- Related development
- References
Gendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists of recombinant adenovirus engineered to code for p53 protein (rAd-p53) and is manufactured by Shenzhen SiBiono GeneTech.
Gendicine was the first gene therapy product to obtain regulatory approval for clinical use in humans after Chinese State Food and Drug Administration approved it in 2003. As of 2024, Gendicine has not been approved for use in the United States and the European Union.
Excerpted from Wikipedia’s “Gendicine” article, available under the CC BY-SA 4.0 licence.